Category: Parkinson’s Disease: Clinical Trials
Objective: To describe the baseline characteristics of Parkinson’s disease (PD) clinical trial participants enrolled in a remote, long-term observational follow-up study.
Background: Participation in clinical research studies is cumbersome and assessments are often restricted to infrequent and time-consuming, in-clinic observation. Mobile and remote technologies may reduce participant burden, permit objective assessment in the home and result in new digital biomarkers of disease progression.
Method: Participants from two completed phase 3 clinical trials of potential disease-modifying therapeutics (SURE-PD3 and STEADY-PDIII) enrolled into AT-HOME PD. This 24-month observational study remotely characterizes long-term clinical outcomes through annual virtual research visits with a remote specialist. Optionally, participants complete quarterly two-week bursts of smartphone-based motor tasks and may opt into passive collection of GPS-based data (mPower). Additionally, participants may enroll in an online companion study, Fox Insight, and complete quarterly participant-reported outcome measures. In a sub-study, we are enrolling up to fifty individuals with PD from a separate on-going, longitudinal, observational study. Sub-study participants complete a single virtual research visit, which will establish the cross-sectional reliability of in-clinic versus virtual assessments (MoCA and MDS-UPDRS).
Results: From the two clinical trials, 350 individuals were pre-screened and 226 completed a baseline visit for AT-HOME PD (mean age (SD) of 64.3 (8.8) years, 39.8% female, 94% white) with participants located in 42 states and Canada. Of the optional study components, 72% of participants enrolled in Fox Insight and 81% in mPower. As of February 25, 2020, 12,714 smartphone-based motor tasks (mean (SD) 71.8 (74)/participant) have been completed with 57 individuals contributing passively collected data. The cohort has a mean (SD) modified MDS-UPDRS (AHPD-U01NS107009) part III score of 24.93 (11.50), Hoehn & Yahr of 1.79 (0.44), Schwab and England of 90.1% (5.6%), and MoCA score of 28 (1.9). Baseline virtual research visits were met with 97% satisfaction.
Conclusion: We successfully enrolled 45% of potentially eligible participants from the parent study cohorts into this long-term remote follow-up study, establishing the infrastructure for a new research model that is well accepted by participants.
To cite this abstract in AMA style:
T. Myers, R. Schneider, L. Omberg, E. Macklin, E. Baloga, P. Snyder, S. Duquette, K. Amodeo, C. Tarolli, J. Adams, C. Lungu, J. Gottesman, E. Kayson, E. Dorsey, L. Mangravite, T. Simuni, M. Schwarzschild. Baseline results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/baseline-results-of-a-virtual-longitudinal-observational-study-of-parkinsons-disease-the-at-home-pd-cohort/. Accessed November 22, 2024.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/baseline-results-of-a-virtual-longitudinal-observational-study-of-parkinsons-disease-the-at-home-pd-cohort/